Aimed Alliance provided comments on Maryland’s SB0357/HB0424, legislation that would enable the Maryland Prescription Drug Affordability Board (PDAB) to establish a process for setting upper payment limits (UPLs) for certain eligible prescription drugs. The legislation would also require the Board to determine whether setting UPLs for all purchases and payor reimbursements is in the state’s best interest to address prescription drug affordability challenges.
In its comment, Aimed Alliance encouraged the Maryland General Assembly to explore alternatives that directly impact consumer cost-sharing, such as implementing a copay accumulator ban. Additionally, the letter urged modifications to the current PDAB law to enhance consumer engagement, representation, and affordability. Specifically, Aimed Alliance recommended:
- Appointing a member to the Board that has lived experience with chronic disease, disability, and/or health equity;
- Requiring the Board to explain how it considered feedback from the Stakeholder Advisory Council;
- Ensuring monitoring of UPLs consider access and affordability challenges developed in relation to the UPL; and
- Ensuring PDAB savings are required to pass through directly to consumers in the form of lower prescription drug costs or lower premiums.
Read the comment here.
Last Updated on February 7, 2025 by Aimed Alliance
